<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604695</url>
  </required_header>
  <id_info>
    <org_study_id>N3770S</org_study_id>
    <nct_id>NCT00604695</nct_id>
  </id_info>
  <brief_title>A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks</brief_title>
  <acronym>ICE T-TIMI 49</acronym>
  <official_title>A Randomized Trial Evaluating Low-Dose IntraCoronary AdjunctivE Tenecteplase During Primary PCI for ST-Elevation Myocardial Infarction (ICE T)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. Michael Gibson, MS, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to gather preliminary data regarding the angiographic
      efficacy of the administration of low-dose adjunctive intracoronary (IC) tenecteplase during
      balloon angioplasty for heart attacks.

      We hypothesize that low-dose IC tenecteplase will enhance the breakdown of blood clots at the
      site of the culprit lesion leading to reduced damage to the heart muscle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to gather preliminary data regarding the angiographic
      efficacy of the administration of low-dose adjunctive intracoronary (IC) tenecteplase during
      primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial
      infarction (STEMI). Efficacy will be assessed by measurements of both the angiographic
      characteristics of the culprit lesion as well as by measurements of epicardial flow and
      myocardial perfusion in the territory of the infarct-related artery. This study will also
      evaluate the safety of administering low-dose IC tenecteplase to subjects undergoing primary
      PCI for STEMI treated with standard therapy (aspirin, clopidogrel, and glycoprotein IIb/IIIa
      inhibitors). Safety endpoints include the incidence of death, recurrent myocardial infarction
      (MI), abrupt vessel closure, subacute stent thrombosis, and TIMI major and minor bleeding
      events.

      Prompt reperfusion therapy with primary PCI in patients with STEMI improves clinical outcomes
      through salvage of myocardial tissue. The proposed pilot trial is a randomized,
      placebo-controlled trial to evaluate the effectiveness and safety of adjunctive low-dose IC
      tenecteplase in conjunction with standard medical therapy during primary PCI for STEMI. We
      hypothesized that low-dose IC tenecteplase will enhance fibrinolysis at the site of the
      culprit lesion leading to reduced microvascular dysfunction. As reduced dose tenecteplase
      will be injected directly into the coronary artery increasing local concentration of the drug
      with minor systemic effects, an improved safety profile is also expected from this mode of
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Diameter Stenosis of the Culprit Lesion Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</measure>
    <time_frame>Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Decrease in Thrombus Grade in the Culprit Artery Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</measure>
    <time_frame>Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Thrombolysis In Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG) of 2 or 3 in the Territory of the Culprit Artery Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</measure>
    <time_frame>Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</time_frame>
    <description>Thrombolysis In Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG) of 2 or 3 in the territory of the culprit artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of Flow Velocity in the Culprit Artery in Terms of Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC)</measure>
    <time_frame>Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</time_frame>
    <description>Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) in the culprit artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hyperemic Flow in the Culprit Artery. That is Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) of Less Than 14</measure>
    <time_frame>Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</time_frame>
    <description>Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) of less than 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Number of Patients Who Developed Thrombolysis In Myocardial Infarction (TIMI) Minor Bleeding</measure>
    <time_frame>Through 30days following PPCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Number of Patients Who Developed Thrombolysis In Myocardial Infarction (TIMI) Minimal Bleeding</measure>
    <time_frame>Through 30days following primary percutaneous coronary intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Number of Patients Who Developed Cardiac Arrhythmias</measure>
    <time_frame>Through 30days following primary percutaneous coronary intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Number of Deaths</measure>
    <time_frame>Through 30days following primary percutaneous coronary intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two (4mg) doses of tenecteplase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two (4mL) doses of sterile saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>Intracoronary injection of IV tenecteplase.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Saline</intervention_name>
    <description>Intracoronary injection of IV sterile saline</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects (men or women) at least 18 years and less than 75 years of age and

          -  Ischemic discomfort ≥20 minutes and ≤6 hours of duration and

          -  ST elevation ≥1mm (≥0.1mV) in two contiguous limb leads OR ≥2mm (≥0.2mV) in two
             contiguous precordial leads and

          -  Occluded infarct-related artery (TIMI Flow Grade 0 or 1) at the time of coronary
             angiography and

          -  Planned primary PCI within 2 hours of hospital presentation and

          -  Planned or concomitant use of aspirin, clopidogrel, unfractionated heparin, and
             Glycoprotein IIb/IIIa inhibition with intent to stent the infarct-related artery and

          -  Informed consent able to be obtained

        Exclusion Criteria:

        CLINICAL

          -  Age ≥75 years

          -  Maximal systolic blood pressure &lt;80 mmHg AFTER initial fluid and/or pressor
             resuscitation.

          -  Uncontrolled hypertension (SBP &gt;180 OR DBP &gt;110) at time of enrollment.

          -  Cardiac arrest or arrhythmia requiring chest compressions or cardiopulmonary
             resuscitation.

          -  Known pregnancy.

        BIOCHEMICAL

          -  Known thrombocytopenia (platelet count &lt;100,000)

          -  Known severe renal insufficiency (creatinine &gt;4.0 mg/dL).

        INCREASED BLEEDING RISK

          -  Active internal bleeding

          -  Recent (&lt;3 months) gastrointestinal hemorrhage

          -  Recent intracranial or intraspinal surgery, trauma, major surgery, or biopsy of a
             parenchymal organ (&lt; 1 month)

          -  Known coagulopathy, platelet disorder, or history of thrombocytopenia

          -  Current warfarin therapy

          -  Known neoplasm

          -  Any known history of transient ischemic attack, cerebrovascular accident, or active
             intracranial pathology including arteriovenous malformation or aneurysm

        MEDICATIONS

          -  Administration of a fibrinolytic agent within 72 hours

          -  Known allergy or contraindication to fibrinolytics OR aspirin OR heparin OR
             clopidogrel

        ANGIOGRAPHIC

          -  Left Main Coronary artery culprit lesion

          -  Ostial culprit lesion (ostium of LAD, LCX, or RCA).

          -  Lesion in non-native coronary artery (e.g. saphenous vein graft, arterial conduit
             graft)

          -  Subjects requiring urgent coronary artery bypass grafting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Michael Gibson, MS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northeast Georgia Heart Center, PC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crittenton Hospital Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Consultants, PC</name>
      <address>
        <city>Freemont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <results_first_submitted>May 15, 2012</results_first_submitted>
  <results_first_submitted_qc>August 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2012</results_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>C. Michael Gibson, MS, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>ST-Elevation Myocardial Infarction</keyword>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>No Reflow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study randomized 40 primary percutaneous coronary intervention (PPCI) patients from 6 hospitals in the United States. The patients were given either a volume matched bolus of intracoronary (IC) tenecteplase (TNK) (4 mg; n=20) or IC saline placebo (4 mg; n=16) before and following PPCI. 4 subjects were randomized but did not receive 1st bolus.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Treatment</title>
          <description>Two (4mg) doses of tenecteplase</description>
        </group>
        <group group_id="P2">
          <title>Placebo Control</title>
          <description>Two (4mL) doses of sterile saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive first bolus.</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Treatment</title>
          <description>Two (4mg) doses of tenecteplase</description>
        </group>
        <group group_id="B2">
          <title>Placebo Control</title>
          <description>Two (4mL) doses of sterile saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="7.6"/>
                    <measurement group_id="B2" value="55.6" spread="8.9"/>
                    <measurement group_id="B3" value="55.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Diameter Stenosis of the Culprit Lesion Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</title>
        <time_frame>Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</time_frame>
        <population>Of the 20 patients randomized to the treatment arm, 4 patients did not meet the inclusion criteria of Thrombolysis In Myocardial Infarction (TIMI) Flow Grade(TFG) 0/1.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis of the Culprit Lesion Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</title>
          <population>Of the 20 patients randomized to the treatment arm, 4 patients did not meet the inclusion criteria of Thrombolysis In Myocardial Infarction (TIMI) Flow Grade(TFG) 0/1.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1.</population>
          <units>Percent diameter stenosis</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Decrease in Thrombus Grade in the Culprit Artery Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</title>
        <time_frame>Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</time_frame>
        <population>Of the 20 patients randomized to the treatment arm, 4 patients did not meet the inclusion criteria of Thrombolysis In Myocardial Infarction (TIMI) Flow Grade(TFG) 0/1.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Decrease in Thrombus Grade in the Culprit Artery Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention</title>
          <population>Of the 20 patients randomized to the treatment arm, 4 patients did not meet the inclusion criteria of Thrombolysis In Myocardial Infarction (TIMI) Flow Grade(TFG) 0/1.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Thrombolysis In Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG) of 2 or 3 in the Territory of the Culprit Artery Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</title>
        <description>Thrombolysis In Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG) of 2 or 3 in the territory of the culprit artery</description>
        <time_frame>Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</time_frame>
        <population>Of the 20 patients randomized to the treatment arm, 4 patients did not meet the inclusion criteria of Thrombolysis In Myocardial Infarction (TIMI) Flow Grade(TFG) 0/1.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Thrombolysis In Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG) of 2 or 3 in the Territory of the Culprit Artery Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</title>
          <description>Thrombolysis In Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG) of 2 or 3 in the territory of the culprit artery</description>
          <population>Of the 20 patients randomized to the treatment arm, 4 patients did not meet the inclusion criteria of Thrombolysis In Myocardial Infarction (TIMI) Flow Grade(TFG) 0/1.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurements of Flow Velocity in the Culprit Artery in Terms of Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC)</title>
        <description>Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) in the culprit artery</description>
        <time_frame>Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</time_frame>
        <population>Of the 20 patients in treatment arm, 4 did not meet the inclusion criteria of TIMI Flow Grade(TFG) 0/1 and cTFC could not be obtained in 4 patients Of the 20 patients in placebo arm, 4 did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1. cTFC could not be obtained in 3 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Measurements of Flow Velocity in the Culprit Artery in Terms of Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC)</title>
          <description>Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) in the culprit artery</description>
          <population>Of the 20 patients in treatment arm, 4 did not meet the inclusion criteria of TIMI Flow Grade(TFG) 0/1 and cTFC could not be obtained in 4 patients Of the 20 patients in placebo arm, 4 did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1. cTFC could not be obtained in 3 patients</population>
          <units>Corrected TIMI Frame Count (cTFC)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="21" upper_limit="33"/>
                    <measurement group_id="O2" value="14" lower_limit="10" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hyperemic Flow in the Culprit Artery. That is Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) of Less Than 14</title>
        <description>Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) of less than 14</description>
        <time_frame>Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug</time_frame>
        <population>Of the 20 patients in treatment arm, 4 did not meet the inclusion criteria of TIMI Flow Grade(TFG) 0/1 and cTFC could not be obtained in 4 patients Of the 20 patients in placebo arm, 4 did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1. cTFC could not be obtained in 3 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hyperemic Flow in the Culprit Artery. That is Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) of Less Than 14</title>
          <description>Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) of less than 14</description>
          <population>Of the 20 patients in treatment arm, 4 did not meet the inclusion criteria of TIMI Flow Grade(TFG) 0/1 and cTFC could not be obtained in 4 patients Of the 20 patients in placebo arm, 4 did not receive the first bolus (drug or placebo) and 3 patients did not meet the inclusion criteria of TFG 0/1. cTFC could not be obtained in 3 patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Number of Patients Who Developed Thrombolysis In Myocardial Infarction (TIMI) Minor Bleeding</title>
        <time_frame>Through 30days following PPCI</time_frame>
        <population>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Patients Who Developed Thrombolysis In Myocardial Infarction (TIMI) Minor Bleeding</title>
          <population>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Number of Patients Who Developed Thrombolysis In Myocardial Infarction (TIMI) Minimal Bleeding</title>
        <time_frame>Through 30days following primary percutaneous coronary intervention</time_frame>
        <population>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Patients Who Developed Thrombolysis In Myocardial Infarction (TIMI) Minimal Bleeding</title>
          <population>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Number of Patients Who Developed Cardiac Arrhythmias</title>
        <time_frame>Through 30days following primary percutaneous coronary intervention</time_frame>
        <population>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Patients Who Developed Cardiac Arrhythmias</title>
          <population>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Number of Deaths</title>
        <time_frame>Through 30days following primary percutaneous coronary intervention</time_frame>
        <population>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Two (4mg) doses of tenecteplase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Control</title>
            <description>Two (4mL) doses of sterile saline</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Number of Deaths</title>
          <population>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30-days following primary percutaneous coronary intervention</time_frame>
      <desc>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Treatment</title>
          <description>Two (4mg) doses of tenecteplase</description>
        </group>
        <group group_id="E2">
          <title>Placebo Control</title>
          <description>Two (4mL) doses of sterile saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Erosive Gastritis</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Cause of death unknown.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Pre-existing anemia.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>High grade Atrio-Ventricular Block</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Pre-existing chronic pancreatitis.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to Bactrim</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Allergic reaction to Lisinopril</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site pain</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Right hand and finger numbness</sub_title>
                <description>Primary percutaneous coronary intervention was performed via radial approach.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Right groin cellulitis</sub_title>
                <description>Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Bleeding at the site of insertion of catheter.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <description>Pre-existing asthma.
Of the 20 patients randomized to the placebo arm, 4 patients did not receive the first bolus (drug or placebo).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator shall furnish Sponsor with copy of any proposed publication for review/comment prior to submission for publication, at least thirty (30) days prior to submission for manuscripts and at least fifteen (15) days prior to submission for abstracts. Institution agrees to delete information identified by Sponsor as Confidential Information prior to submission for publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This pilot study was not adequately powered to exclude a modest increase in bleeding events. Study drug could not be administered to 4 patients and 7 patients were excluded for not meeting the inclusion criteria of TIMI Flow Grade 0/1 at enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>C. Michael Gibson, MS, MD</name_or_title>
      <organization>Brigham &amp; Women's Hospital</organization>
      <phone>617-632-7753</phone>
      <email>mgibson@perfuse.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

